Purpose: Osteogenesis imperfecta (OI) predisposes people to recurrent fractures, bone deformities, and short stature. There is a lack of large-scale systematic studies that have investigated growth parameters in OI.
INTRODUCTION
Osteogenesis imperfecta (OI)-a group of Mendelian disorders of connective tissue (MIM 166200, 166210, 259420, 166220, 610967, 613982, 610682, 610915, 259440, 613848, 610968, 609220, 614856, 613849, 615066, 615220, 616229, 616507)predisposes people to recurrent fractures, bone deformities, and short stature. 1 Nearly 90% of individuals with OI have pathogenic variants in COL1A1 and COL1A2 that encode for the α1 and α2 chains of type I collagen-a major protein of the bone matrix. 2 Over the past decade, the discovery of numerous genes as causes for OI has underscored the genetic heterogeneity of this disorder. However, the Sillence classification, which was proposed well before the genetic basis of OI was known, continues to be used for management and counseling purposes. 3 Accordingly, the autosomal dominant, type-Icollagen-related OI is classified into nondeforming (type I), perinatally lethal (type II), progressively deforming (type III), and common variable (type IV) forms. Short stature is a hallmark of the moderate-to-severe forms of OI. Previous studies have demonstrated that the mean birth length and weight in individuals with OI are below the normative data from the general population. 4, 5 Whereas final height is significantly restricted in those with OI types III and IV, even those with milder forms of disease (i.e., type I), have reductions in overall height compared with the general population. [5] [6] [7] [8] To date, few studies have systematically analyzed the growth parameters in OI. Most reports are limited either by the size of the cohort or the lack of data on adults with OI 5, 6, [8] [9] [10] [11] [12] [13] . In fact, there are only two studies outlining the growth parameters in both children and adults with OI. 7, 8 The largest cohort of both children and adults with OI described to date (144 children and 199 adults) revealed that, in addition to decreased height, obesity is common in OI. 7 Detailed assessments of anthropometric measures in OI can have both diagnostic and management implications. Appropriate characterization of the growth parameters can help identify affected individuals who are not meeting the expected growth patterns and institute lifestyle modifications for weight control.
Here, we analyzed the cross-sectional growth parameters in a large cohort of individuals with OI from across North America (n = 552; 408 children and 144 adults) who were enrolled in the observational study "Longitudinal Study of Osteogenesis Imperfecta" that was conducted by the OI Linked Clinical Research Centers (LCRC). 14 The large sample size of the cohort allowed us to examine growth parameters in the various subtypes of OI, and assess the potential correlations between height and the type of OI, surgical rodding, and bisphosphonate use.
MATERIALS AND METHODS

Study population
Details of the LCRC and Longitudinal Study of Osteogenesis Imperfecta have been described previously. 14 At the clinical sites, demographic data, medical history, and anthropometric measures of height, weight, and arm span were collected and recorded in a uniform fashion by trained personnel. Height, weight, and arm span were recorded as single measurements. The data were collected at every clinical site in accordance with the instructions outlined in the Manual of Operations developed for the multi-site study, thus ensuring consistency between the clinical sites. Parameters were reported using online case report forms as follows.
• Height was defined as the vertical distance between the crown of the head and soles of the feet. It was measured using a wall-mounted stadiometer and recorded to the nearest 0.1 cm. When participants could not stand, the supine length was measured from the heels to the top of the head.
• Weight was measured on an upright calibrated digital or beam scale to the nearest 0.1 kg. In individuals who were too young to stand alone, an infant scale was used. When children could not stand on the scales, they were weighed while being held by a parent, and the weight of the child was calculated by subtracting the weight of the parent from the total weight. The body mass index (BMI) was calculated as weight (kg)/height (m). 2
• Arm span was measured as the distance from one furthermost fingertip to the other furthermost fingertip when the participant's arms were stretched out horizontally, using a nonstretching long measuring tape to the nearest 0.1 cm. Arm span was measured as a single measure, as opposed to parts then added together.
Overall, 552 participants were enrolled, including 244 with OI type I, 110 with OI type III, 150 with OI type IV, 15 with OI type V, 12 with OI type VI, 5 with OI type VII, and 16 with an unclassified type of OI . The classification of OI was based on clinical features outlined in the Manual of Operations; however, genotypic information was used to reclassify patients when available. Data collected for analyses included age at enrollment, sex, OI type, family history of OI, history of bisphosphonate use (yes or no), history of rodding (yes or no), self-reported parental height, subject height, weight, and arm span. To analyze height within particular genotypes, we classified the type I collagen pathogenic variant (PV) as glycine substitution PV within the triple helix domain (n = 160), loss-of-function (nonsense, deletion, frameshift, or splicing; n = 144) PV and nonglycine missense variations (n = 9). Given the small number of individuals with OI types V, VI, and VII, they were excluded from further formal statistical evaluations. The height, weight, and BMI data presented here were collected at the initial enrollment visit.
Statistical analysis
For participants below 20 years of age (OI type I, n = 163; OI type III, n = 83; OI type IV, n = 123), the Centers for Disease Control and Prevention's (CDC's) growth curves were utilized to plot the height, weight, and BMI. The z-scores were calculated using the L, M, and S parameters based on the methodology described previously. 15 The z-scores were computed using the AGD library in R. To compare z-scores for height, weight, and BMI between the OI types, a Komogrov-Smirnov test was performed to evaluate for normal distribution (analysis of variance, or analysis of variance on ranks, were used as appropriate). When comparing z-scores for height, weight, and BMI between OI types, we categorized individuals into age groups of 0-5 years, 5-10 years, 10-15 years, 15-20 years, and >20 years. Z-scores for height and weight for individuals >20 years of age were calculated using normative values from 20-year-old individuals. The differences in proportions of individuals below the third percentile for height and weight between the OI types were analyzed using Fisher's exact tests. For adult participants in the study (OI type I, n = 81; OI type III, n = 27; and OI type IV, n = 27) the expected midparental height was calculated from self-reported parental heights, and 5 cm was considered to be 1 SD from the mean, as previously published. 16 The differences in proportions of individuals with final heights below 2 SD from the expected height were analyzed using Fisher's exact tests. The growth velocity between OI subtypes was assessed, and the proportion of individuals falling outside of 2 SD from the mean based on normative data was ascertained. 17 To further evaluate the potential effects of age, history of orthopedic rodding, history of bisphosphonate use, and sex on height, we performed generalized linear model analyses using a backward elimination strategy with the 'step' function in R. The height z-score was the dependent variable, while the independent categorical variables included OI type (type I, III, or IV), sex (male or female), history of rodding (yes or no), and history of bisphosphonate therapy (yes or no); age was included as a continuous numeric variable. P values were calculated using the likelihood ratio test, and correlations present with P < 0.05 were tested for evidence of interaction.
The arm-span-to-height ratios between OI subtypes were compared by one-way analysis of variance among the age groups <10 years, 10-20 years, and >20 years. These age categories were chosen based on previous normative data that show an increase in the arm-span-to-height ratio after 10 years of age. 18 
RESULTS
The characteristics of individuals enrolled in the study are outlined in Table 1 . The autosomal dominant forms of type I collagen-related OI accounted for over 90% of all enrolled individuals.
Height in OI
In the pediatric population (age <20 years), the median (interquartile range (IQR)) z-scores for height in OI types I, III, IV, V, and VI were −0.66 (−1.43 to −0.02), −6.91 (−8.41 to −5.17), −2.79 (−3.95 to −1.69), −1.65 (−2.16 to −0.77), and −1.72 (−2.36 to −1.38), respectively ( Figure 1) . As expected, for the type I collagen-related OI across all age groups, individuals with OI type III had diminished height compared with OI type I and OI type IV, and individuals with OI type IV had decreased height compared with OI type I (P < 0.05). When plotted on CDC growth curves, 9.5% of males and 18.1% of females with OI type I, 97.4% of males and 95.5% of females with OI type III, and 70.4% of males and 68.9% of females with OI type IV were below the third percentile for height ( Figure 2) . The odds ratio (95% confidence interval) for being below the third percentile was 219 (50.5-953.4) for OI type III (P < 0.001 compared with type I) and 11.7 (6.5-20.9) for OI type IV (P < 0.001 compared with type I). For OI type III, the odds ratio for being below the third percentile was 18.76 (4.37-80.45; P < 0.001 compared with OI type IV).
In adults with OI, the median (IQR) z-scores for height were −1.10 (−1.90 to −0.38), −8.67 (−9.99 to −6.85), and for type III compared with type IV (P < 0.001) and type I OI (P < 0.01), but no statistically significant difference was noted between OI types I and IV. We correlated the height z-scores with PV type in individuals who had demonstrated pathogenic variants in either COL1A1 or COL1A2. For individuals with glycine substitution PV the median height z-score (IQR) was −4.7 (−6.7 to −2.1); for individuals with other missense variants, it was −3.5 (−1.7 to −5.2); and for loss-of-function variants, it was −1.28 (−2.2 to −0.72). Height was significantly diminished in individuals with glycine substitutions compared with loss of function (P < 0.001). Furthermore, we examined whether different glycine substitutions had an effect on height. Individuals with glycine-to-serine substitutions had a median height z-score of −5.6 (−6.7 to −3.1), whereas the median heights in glycine-to-aspartate and glycine-toanother-amino-acid substitutions were −3.5 (−5.5 to −3.2) and −3.2 (−6.8 to −1.7), respectively. While the median was lower for glycine-to-serine substitutions, this difference did not reach statistical significance.
Growth velocity in OI
We used the longitudinal aspect of the cohort to examine growth velocity in participants between the ages of 3 and 16 years. We selected individuals who had at least two height measurements separated by 6 to 18 months. The velocity of growth was calculated in cm•year -1 and the value obtained was plotted against normative data. In individuals with three or more measurements, the values between two consecutive measurements were considered as distinct data points and thus plotted separately. In total, 127 individuals with OI type I (n = 61 male; n = 66 female; n = 259 growth velocity measurements), 46 individuals with OI type III (n = 20 male; n = 26 female, n = 79 growth velocity measurements), and 76 individuals with OI type IV (n = 37 male, n = 39 female, Figure S1 online) . Analysis of variance on ranks demonstrated significant differences between the OI subtypes across all age groups, with weight in OI type III being significantly lower than in OI types I and IV (P < 0.05). We observed significant differences for weight between OI types IV and I only in the age groups 0-5 years and 10-15 years (P < 0.05). As for height, a similar relationship was seen for weight, where 11.8% of males and 16.9% of females with OI type I, 35 .8% of males and 33.3% of females with OI type IV, and 94.7% of males and 84.8% of females with OI type III were below the third percentile (P < 0.001; Figure 3 ). The odds ratios (95% confidence interval) for being below the third percentile were 43.20 (19.50-95.69) for OI type III (P < 0.001 compared with type I) and 15.76 (7.32-33.95) for OI type IV (P < 0.001 compared with type I). For individuals with OI type III compared with OI type IV, the odds ratio for being below the third percentile was 2.74 (1.52-4.94; P < 0.005).
BMI in OI
The median (IQT) z-scores for BMI in the pediatric population for OI types I, III, and IV were 0.10 (−0.58 to 0.94), 0.91 (0.42 to 1.61) and 0.67 (−0.18 to 1.33) (Figure 4 and Supplementary  Figure S2 online). When BMI was calculated using measured height, individuals with OI type III had increased BMI compared with OI types I and IV in adults and children in the age groups 5-10 years and 15-20 years (P < 0.05).
Arm-span-to-height ratio in OI
The arm-span-to-height ratio is an indicator of the relative severity of linear growth abnormalities of the axial and/or lower limb compared with the upper limbs. The adult arm span is typically 5 cm greater in males and 2 cm greater in females compared with height. 18 Arm-span-to-height ratios change with age; i.e., the arm span is less than height in early childhood, equal to height by about 10 years in males and 12 years in females, and greater than height thereafter. 18 Thus, we compared the arm-span-to-height ratio in the age groups <10 years, 10-20 years, and >20 years. Only in the >20 years group did we observe significant increased arm-span-toheight ratios in OI types III and IV compared with type I (P < 0.001 and P < 0.05, respectively) ( Supplementary Figure S3 online).
Potential correlates affecting height in OI
Previous studies have shown that individuals with severe forms of OI can have "flattening" of their height curves so that the height z-scores worsen with age. 7, 8 With the widespread use of bisphosphonates, the effect of the medications on linear growth has been assessed in short-term studies without conclusive answers. [19] [20] [21] [22] [23] To understand the correlations between some covariates and the height z-scores, we performed a generalized linear model analysis. As expected, OI subtype was strongly correlated with the height z-scores through all pediatric ages (P < 0.001). Increasing age correlated with reduced height z-scores (P < 0.05). Independent correlations were also observed for history of rodding (P < 0.01) and use of bisphosphonates (P < 0.05), where both of these covariates correlated with overall reduced z-scores. However, there were significant interactions between the OI subtype, history of rodding, and bisphosphonate use. Thus, we could not independently assess the effects of these covariates on height.
DISCUSSION
OI is a clinically heterogeneous disorder characterized by an increased predisposition to recurrent fractures and bone deformities. 3 Although it is well recognized that growth deficiency can be found in patients with severe forms of OI, there is a lack of large-scale studies on growth parameters in various subtypes of OI. In this study, we included a large cohort of children and adults with OI from multiple clinical centers in North America. The height measurements in this cohort are consistent with the expected phenotypes for OI and growth patterns observed in other studies. 3, [5] [6] [7] [8] Height in OI type III is more severely affected compared with OI types I and IV. Although some individuals with OI types I and IV can have heights within the normal range, the overall adult height is affected in all subtypes. Even in OI type I (the mildest form), the final height in nearly half of individuals is 2 SD below the expected midparental height. Given these distinct patterns of height, height z-scores could be utilized for clinical classification of type I collagen-related OI.
The etiology for short stature in OI is multifactorial. Scoliosis, kyphosis, vertebral fractures, recurrent long bone fractures, and bone deformities are important contributing factors. The incidence of scoliosis and the rate of progression of curvature are significantly higher in the more severe forms of OI. 24 In a retrospective study of over 300 children with OI, Anissipour and colleagues found that the rates of progression of scoliosis were 6°, 4°, and 1°in OI types III, IV, and I, respectively. Spinal deformities in the severe forms of OI can lead to a reduction in truncal height. Similarly, fractures and bowing of the femur and tibia, fractures occurring through the growth plates, and abnormalities of the epiphyses in the severe forms of OI lead to decreased limb length and overall height. The varying severity of involvement of the axial and appendicular skeleton can be reflected by the arm-span-toheight ratio. In this study, we observed that the arm-span-toheight ratio was increased in adults with types III and IV OI compared with type I. These results are consistent with previous observations. 6, 8 Collectively, these findings suggest that truncal height is relatively more reduced than the length of the long bones in the more severe forms of OI.
However, clinical experience and previous studies have demonstrated that overall height can be affected even in individuals without significant bone deformities. 7, 8 Thus, it has been hypothesized that the primary matrix and cellular abnormalities may have a role in the decreased growth rates in OI. Decreased responsiveness to growth hormone and insulin-like growth factor 1 has been suggested as one of the mechanisms in a few studies. 25, 26 More recently, it was discovered that excessive transforming growth factor-beta (TGF-β) signaling is an important driver of the bone and extraskeletal abnormalities in moderate-to-severe forms of OI. 27 The collagen overmodification in severe forms of OI affects the interaction of type I collagen with small leucinerich proteoglycans that bind TGF-β, which results in increased availability of the ligand. [27] [28] [29] [30] Increased TGF-β signaling in the growth plate could affect bone growth. In a mouse model of E-selectin ligand (a negative regulator of TGF-β) deficiency, Yang and colleagues demonstrated reduced chondrocyte proliferation and delayed terminal differentiation. 31 Thus, it is possible that increased TGF-β signaling could contribute to the abnormal growth in OI. While final adult height is affected across all types of OI, using the longitudinal nature of the dataset, we also demonstrate that the growth velocity is affected. Current information on growth velocity in OI patients is rather limited, and studies that have addressed this have done so in the context of therapy. 11, 32, 33 It is not known whether the decreased growth velocity in OI type III and IV is driven by the recurrent fractures or intrinsic abnormalities of the bone and cartilage.
Bisphosphonates are currently considered a standard-ofcare and are widely used for the treatment of individuals with OI, but the effects of bisphosphonates on fracture risk in OI are difficult to address and the results have been inconclusive. [19] [20] [21] [22] [23] [33] [34] [35] [36] [37] Few studies have addressed the effects of bisphosphonates on height in OI. Zeitlin and colleagues showed that four years of therapy with pamidronate increased height z-scores in children with moderate-to-severe OI. 11 Similarly, it has also been shown that bisphosphonate therapy decreases the rate of progression of scoliosis in type III OI if treatment is started before the age of six years; 24 however, recent meta-analyses have not shown a significant effect of bisphosphonates on height. 38, 39 In this study, we tried to find correlations between height z-scores and the use of bisphosphonates. In our cohort, 30% of individuals with OI type I, 84% with OI type III, and 76% with OI type IV had received intravenous bisphosphonate at some time, and 15% in each subtype had received oral bisphosphonates. However, on generalized linear model analyses, there was a significant interaction between the OI subtype and the use of bisphosphonates, and the proportion of individuals with severe OI who were naïve to bisphosphonates was very low, precluding independent assessment of the effect of bisphosphonates on height.
Weight in OI has not been studied as extensively as height. In this report, we observed that individuals with OI type III continue to fall below the third percentile of the CDC growth curves across all age groups. These results are consistent with previous publications reporting that individuals with severe OI are underweight. 6 However, in spite of the lower weight, the calculated BMI in OI tends to be higher, especially in OI type III. Using peripheral quantitative computed tomography, Palomo and colleagues showed that the fat cross-sectional area at the forearm in individuals with OI is similar to the control population. 40 These data imply that "increased BMI" is a result of the small value of the denominator during calculation and may not portend increased metabolic risks. It may thus be more important and practical to monitor serial weight in OI, especially in adults. Future studies that systematically measure body composition in OI may be helpful in risk stratification and further management.
Disorder-specific growth charts can be very helpful in monitoring growth in the clinic. To our knowledge, the only growth charts that have been developed in OI are for OI type I. 13 One challenge in creating standard growth charts for all subtypes of OI is the great variability in the clinical presentations. The experience gained for the studies in the OI LCRC was pivotal in establishing the Brittle Bone Disorders Consortium (BBDC). The data being collected in the BBDC would be helpful in generating OI-specific growth curves for all subtypes of OI.
In summary, our analyses of the largest cohort of individuals with OI demonstrates that individuals with severe forms of OI have reduced height as well as weight compared with those with type I OI. This important study is a significant first step in the construction of growth curves for this disorder.
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